Patents by Inventor Ashraf S. Ibrahim

Ashraf S. Ibrahim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220354935
    Abstract: The invention provides a vaccine against inflammatory bowel disease (IBD), such as Crohn's disease, ulcerative colitis, and the like. The vaccine comprises a polypeptide comprising a Candida adhesin antigen, typically an isolated agglutinin-like sequence (Als) protein antigen, formulated with one or more pharmaceutically acceptable carriers or excipients.
    Type: Application
    Filed: April 21, 2022
    Publication date: November 10, 2022
    Inventors: Ashraf S. IBRAHIM, June L. ROUND, Kyla OST
  • Publication number: 20210179695
    Abstract: Presented herein, in certain aspects, are compositions that comprise novel toxin proteins, the nucleic acids that encode them, and/or portions thereof, which toxins are expressed by fungi of the Mucorales order and are thought to contribute to the pathogenesis of Mucormycosis. Also presented herein, in certain aspects, are methods of detecting the presence or absence of novel fungal toxins and/or the nucleic adds that encode them in a sample, which methods can be used to identify the presence of Mucorales in a subject. Methods and/or compositions presented herein can be used to prevent and/or treat a Mucorales infection.
    Type: Application
    Filed: December 10, 2020
    Publication date: June 17, 2021
    Inventors: Ashraf S. IBRAHIM, Sameh SOLIMAN, John EDWARDS, JR.
  • Publication number: 20210030852
    Abstract: Disclosed herein are compositions and methods for treating and immunizing against C. auris infection and colonization. The compositions and methods include polypeptides and fragments derived from the C. albicans Als3 protein, homologs thereof, and antibodies or fragments thereof that specifically bind these polypeptides and fragments. Administration of these compositions confers treatment and resistance against C. auris infection and colonization.
    Type: Application
    Filed: April 10, 2018
    Publication date: February 4, 2021
    Inventors: John E. EDWARDS, Jr., Shakti SINGH, Ashraf S. IBRAHIM, Priya UPPULURI
  • Patent number: 10877037
    Abstract: Presented herein, in certain aspects, are compositions that comprise novel toxin proteins, the nucleic acids that encode them, and/or portions thereof, which toxins are expressed by fungi of the Mucorales order and are thought to contribute to the pathogenesis of Mucormycosis. Also presented herein, in certain aspects, are methods of detecting the presence or absence of novel fungal toxins and/or the nucleic acids that encode them in a sample, which methods can be used to identify the presence of Mucorales in a subject. Methods and/or compositions presented herein can be used to prevent and/or treat a Mucorales infection.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: December 29, 2020
    Assignee: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
    Inventors: Ashraf S. Ibrahim, Sameh Soliman, John Edwards, Jr.
  • Patent number: 10653757
    Abstract: The invention features a method of vaccinating a mammal against Staphylococcus aureus which includes the steps of: a) identifying a mammal at risk for the development of a Staphylococcus aureus skin or soft tissue infection; and b) administering to said mammal an immunogenic amount of a vaccine that includes a polypeptide including an isolated agglutinin-like sequence (Als) 3 protein (Als3p), or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: May 19, 2020
    Assignees: NovaDigm Therapeutics, Inc., Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Michael R. Yeaman, John E. Edwards, Jr., Scott G. Filler, Ashraf S. Ibrahim, Yue Fu, John P. Hennessey, Jr.
  • Publication number: 20190265238
    Abstract: Presented herein, in certain aspects, are compositions that comprise novel toxin proteins, the nucleic acids that encode them, and/or portions thereof, which toxins are expressed by fungi of the Mucorales order and are thought to contribute to the pathogenesis of Mucormycosis. Also presented herein, in certain aspects, are methods of detecting the presence or absence of novel fungal toxins and/or the nucleic acids that encode them in a sample, which methods can be used to identify the presence of Mucorales in a subject. Methods and/or compositions presented herein can be used to prevent and/or treat a Mucorales infection.
    Type: Application
    Filed: November 20, 2017
    Publication date: August 29, 2019
    Inventors: Ashraf S. IBRAHIM, Sameh SOLIMAN, John EDWARDS, Jr.
  • Publication number: 20190194301
    Abstract: The invention provided Mucorales CotH antibodies, polypeptides, encoding nucleic acid molecules, and uses thereof. The Mucorales CotH antibodies, polypeptides and encoding nucleic acids disclosed herein can be advantageously used to diagnose, treat or prevent fungal conditions, in particular mucormycosis.
    Type: Application
    Filed: December 11, 2018
    Publication date: June 27, 2019
    Inventors: Ashraf S. Ibrahim, Mingfu Liu, Teklegiorgis Ghebremariam, Yue Fu, John E. Edwards, Scott Filler
  • Patent number: 10300120
    Abstract: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of Candida to a host cell or tissue.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: May 28, 2019
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: John E. Edwards, Jr., Ashraf S. Ibrahim, Bradley J. Spellberg, Yue Fu, Scott G. Filler, Michael R. Yeaman
  • Publication number: 20190030141
    Abstract: The invention features fragments of the Candida cell surface proteins Als3 and Hyr1 and combinations thereof useful in immunizing a subject against fungal or bacterial infections or both.
    Type: Application
    Filed: October 11, 2018
    Publication date: January 31, 2019
    Inventors: Ashraf S. Ibrahim, Michael R. Yeaman, Scott G. Filler, John E. Edwards, JR., John P. Hennessey, JR.
  • Patent number: 10160790
    Abstract: The disclosure features isolated polypeptides of Hyr1. The disclosure further features vaccines and antibodies useful in treating or preventing candidiasis or Acinetobacter infections or both. Further disclosed are isolated polypeptides consisting of between 14 and 20 amino acids for vaccine preparation. The specific amino acid sequences of isolated polypeptides of Hyr1 are also disclosed.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 25, 2018
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Ashraf S. Ibrahim, Michael R. Yeaman, John E. Edwards, Jr., Guanpingsheng Luo, Yue Fu
  • Patent number: 10130691
    Abstract: The invention features fragments of the Candida cell surface proteins Als3 and Hyr1 and combinations thereof useful in immunizing a subject against fungal or bacterial infections or both.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 20, 2018
    Assignees: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, NovaDigm Therapeutics, Inc.
    Inventors: Ashraf S. Ibrahim, Michael R. Yeaman, Scott G. Filler, John E. Edwards, Jr., John P. Hennessey, Jr.
  • Publication number: 20170173153
    Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.
    Type: Application
    Filed: June 13, 2016
    Publication date: June 22, 2017
    Inventors: John E. EDWARDS, JR., Scott G. FILLER, Donald C. SHEPPARD, Ashraf S. IBRAHIM, Yue FU, Brad J. SPELLBERG
  • Publication number: 20160220648
    Abstract: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of Candida to a host cell or tissue.
    Type: Application
    Filed: February 3, 2016
    Publication date: August 4, 2016
    Inventors: John E. EDWARDS, Jr., Ashraf S. IBRAHIM, Brad J. SPELLBERG, Yue FU, Scott G. FILLER, Michael R. YEAMAN
  • Patent number: 9364539
    Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: June 14, 2016
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: John E. Edwards, Jr., Scott G. Filler, Donald C. Sheppard, Ashraf S. Ibrahim, Yue Fu, Brad J. Spellberg
  • Publication number: 20160159887
    Abstract: The invention provided Mucorales CotH antibodies, polypeptides, encoding nucleic acid molecules, and uses thereof. The Mucorales CotH antibodies, polypeptides and encoding nucleic acids disclosed herein can be advantageously used to diagnose, treat or prevent fungal conditions, in particular mucormycosis.
    Type: Application
    Filed: February 12, 2016
    Publication date: June 9, 2016
    Inventors: Ashraf S. IBRAHIM, Mingfu LIU, Teklegiorgis GHEBREMARIAM, Yue FU, John E. EDWARDS, Scott FILLER
  • Publication number: 20160130330
    Abstract: The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include antibody, antibody fragments, siRNA and vaccine compositions having or directed against a GRP78 polypeptide or an antigenic fragment of the polypeptide.
    Type: Application
    Filed: January 8, 2016
    Publication date: May 12, 2016
    Inventors: Ashraf S. Ibrahim, Mingfu Liu, Brad J. Spellberg, Scott Filler, Yue Fu, John E. Edwards
  • Patent number: 9279002
    Abstract: The invention provided Mucorales CotH polypeptides and encoding nucleic acid molecules. The Mucorales CotH polypeptides and encoding nucleic acids can be advantageously used to diagnose, treat or prevent fungal conditions, in particular mucormycosis.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 8, 2016
    Assignee: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
    Inventors: Ashraf S. Ibrahim, Mingfu Liu, Teklegiorgis Ghebremariam, Yue Fu, John E. Edwards, Scott Filler
  • Patent number: 9259467
    Abstract: The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include antibody, antibody fragment, siRNA and vaccine compositions having or directed against a GRP78 polypeptide or an antigenic fragment of the polypeptide.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: February 16, 2016
    Assignee: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
    Inventors: Ashraf S. Ibrahim, Mingfu Liu, Brad Spellberg, Scott Filler, Yue Fu, John E. Edwards
  • Publication number: 20160030534
    Abstract: The invention features fragments of the Candida cell surface proteins Als3 and Hyr1 and combinations thereof useful in immunizing a subject against fungal or bacterial infections or both.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Applicants: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, NovaDigm Therapeutics, Inc.
    Inventors: Ashraf S. IBRAHIM, Michael R. YEAMAN, Scott G. FILLER, John E. EDWARDS, JR., John P. HENNESSEY, JR.
  • Publication number: 20160030533
    Abstract: The invention features isolated polypeptides and conjugates including the amino acid sequence of any one of SEQ ID NOs: 3-11, or a variant sequence thereof having up to three substitutions, deletions, or additions to the amino acid sequence of any one of SEQ ID NOs: 3-11, wherein the polypeptide does not include more than 20 contiguous amino acids of SEQ ID NO: 2 or SEQ ID NO: 17. Additional polypeptides includes those of formula (I) [ZNZPVSSBSFSYT]n and formula (II) [ZNUWOOBUFOYT]n. The invention further features vaccines including such polypeptides or conjugates and methods of vaccination against candidiasis or a staphylococcal infection of both using same. In addition, the invention features antibodies that bind to the polypeptides or conjugates, and methods of passive immunization using same.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: Michael R. YEAMAN, Ashraf S. IBRAHIM, Scott G. FILLER, John E. EDWARDS, JR.